Sensitivity to Vγ9Vδ2TCR T cells is imprinted after single mutations during early oncogenesis

Astrid Cleven,Angelo D. Meringa,Peter Brazda,Domenico Fasci,Thijs Koorman,Tineke Aarts,Inez Johanna,Dennis X Beringer,Patricia Hernandez-Lopez,Sabine Heijhuurs,Tomohiro Mizutani,Sangho Lim,Maarten Huismans,Jochem Bernink,David Vargas Diaz,Wei Wu,Esther San Jose,Jelle Schipper,Nikos Tsakirakis,Lauren Hoorens van Heyningen,Annick Nouwens,Lucrezia Gatti,Trudy Straetemans,Hugo Snippert,Jeanine Roodhart,Patrick W.B. Derksen,Jarno Drost,Maarten Altelaar,Albert J.R. Heck,Hans Clevers,Juergen Kuball,Zsolt Sebestyen
DOI: https://doi.org/10.1101/2024.11.19.624272
2024-11-21
Abstract:Vγ9Vδ2T cells have the unique ability to recognize a broad range of malignant transformed cells. The tumor targeting event involving BTN2A1 and BTN3A1 dimers on the tumor cell surface is critical, leading to full activation of the TCR. Although the molecular mechanisms governing TCR engagement and T cell activation are well-characterized, the role of Vγ9Vδ2 T cells in cancer immune surveillance remains to be fully elucidated, particularly the mechanisms that enable these cells to discriminate between healthy and malignant cells at an early stage of malignant transformation. We employed two independent, genetically engineered step-wise mutagenesis models of human colorectal and breast cancer that mimic the transformation steps leading to tumor formation. We demonstrate that various single oncogenic mutations introduced into healthy organoids or cells, are sufficient to upregulate surface expressed BTN2A1 and enable Vγ9Vδ2 TCR binding to tumor cells. However, full activation of T cells through a Vγ9Vδ2TCR required additional subsequent phosphorylation of juxtamembrane (JTM) amino acids of BTN3A1, leading to the activating heterodimerization of BTN2A1 and 3A1. Using a protein interactome mapping pipeline, we identified PHLDB2, SYNJ2 and CARMIL1 as key players in controlling these delicate dual surface dynamics of BTN2A1 and 3A1 during early transformation. This mode of action allowed Vγ9Vδ2TCR T cells to control tumors in vitro and in vivo, emphasizing the crucial role of these molecules from early mutagenesis, to advanced cancer stages, and highlighting the therapeutic potential of a Vγ9Vδ2TCR.
Biology
What problem does this paper attempt to address?
The key problem that this paper attempts to solve is: **How do Vγ9Vδ2 T cells recognize and target tumor cells during the early malignant transformation stage?** Specifically, the research aims to reveal how the TCR (T - cell receptor) of Vγ9Vδ2 T cells distinguishes healthy cells from malignantly transformed cells through specific molecular mechanisms, and to explore the role of these mechanisms in cancer immunosurveillance. ### Main problem decomposition: 1. **Sensitivity of Vγ9Vδ2 T cells in early malignant transformation**: - The researchers used step - wise mutagenesis models to simulate the early malignant transformation processes of colorectal cancer and breast cancer. - They found that a single oncogenic mutation is sufficient to make the BTN2A1 protein expressed on the surface of healthy organoids or cells, thus allowing the Vγ9Vδ2 TCR to bind to tumor cells. 2. **Conditions for full activation of Vγ9Vδ2 T cells**: - Full activation of Vγ9Vδ2 T cells requires not only the expression of BTN2A1, but also the phosphorylation of amino acids in the juxtamembrane region (JTM) of BTN3A1, which leads to the formation of an activating heterodimer of BTN2A1 and BTN3A1. 3. **Identification of key regulatory molecules**: - Through proteomic interaction analysis, the researchers identified key molecules such as PHLDB2, SYNJ2 and CARMIL1, which control the surface dynamic changes of BTN2A1 and BTN3A1 during the early transformation process. 4. **Role of the PI3K/AKT/mTOR signaling pathway**: - Research shows that the PI3K/AKT/mTOR signaling pathway plays a crucial role in early malignant transformation. It drives the surface expression of BTN2A1, thus making tumor cells sensitive to Vγ9Vδ2 TCR. ### Conclusion: This research reveals the specific mechanisms by which Vγ9Vδ2 T cells recognize tumor cells during the early malignant transformation stage, emphasizing the important role of these cells in cancer immunosurveillance. In particular, the study has discovered the key roles of the PI3K/AKT/mTOR signaling pathway and specific molecules such as PHLDB2, SYNJ2 and CARMIL1 in this process, providing new ideas and potential targets for the development of Vγ9Vδ2 TCR - based cancer immunotherapy. ### Formula presentation: - **PI3K/AKT/mTOR signaling pathway**: \[ \text{PI3K} \rightarrow \text{AKT} \rightarrow \text{mTOR} \] - **Formation of the heterodimer of BTN2A1 and BTN3A1**: \[ \text{BTN2A1} + \text{p - BTN3A1} \rightarrow (\text{BTN2A1}:\text{p - BTN3A1})_{\text{heterodimer}} \] These findings not only deepen our understanding of the function of Vγ9Vδ2 T cells, but also provide new directions for future cancer treatment.